Anti-human Neuropilin-1 b1b2 [clone 7E8; mAB3] Monoclonal Antibody
Invented at University of Tartu
- Datasheet
- References (2)
- Inventor Info
Info
![Image thumbnail for Anti-human Neuropilin-1 b1b2 [clone 7E8; mAB3] Monoclonal Antibody](https://res.cloudinary.com/ximbio/image/upload/c_fit,fl_lossy,h_45,q_auto/412c3597-d041-422b-9937-f40429cae531.jpg)
| Catalogue Number | 160471 |
| Applications | IHC IF WB |
| Antigen/Gene or Protein Targets | human Neuropillin-1 b1b2 domain |
| Synonyms | 7E8, mAb3 (mAB3 in studies published in Science) |
| Reactivity | Human |
| Relevance |
Monoclonal antibody raised against human NRP-1 b1b2 domain, clone 7E8 (mAB3 in studies published in Science). Complete blockade of CendR peptides to b1 domain of NRP-1. In recent years the relevance of CendR pathway for cellular uptake of biological nanoparticles – viruses - has been demonstrated in several independent studies. A direct role of Neuropilin (NRP) in virus entry has been demonstrated for three viruses, the retrovirus Human T-cell lymphotropic virus type 1 (HTLV-1) and the herpes viruses EBV and CMV5-8. In the case of CMV, NRP-2 acts as a receptor only for specific cell types, while in fibroblasts the virus uses a different molecule for entry. Viruses that display CendR peptides on their surface are expected to bind a specific CendR binding pocket on the extracellular domain of NRP. Ample evidence obtained with synthetic and phage-displayed CendR peptides shows that they bind to conserved binding pocket in b1 domain of NRP-1. The inventors have developed a monoclonal antibody that specifically interacts with the CendR binding pocket of the b1 domain of Neuropilin-1 and blocks binding of CendR peptides. This monoclonal antibody has potential applications in the research of SARS-CoV2 in that the antibody is capable to reduce/block the internalisation of SARS-CoV2 into cells, thus to stop viral replication. |
| Host | Mouse |
| Immunogen | Human wild-type Neuropilin-1 CendR b1b2 region |
| Myeloma Used | P3X63Ag8.653 |
| Notes |
This technology is part of a series of anti- human Neuropilin-1 b1b2 domain mAbs. Two other clones, as well as the expression cosntruct for the immunogen, are available on Ximbio.com (see Related tab). 1A4 - mAB1 Partial CendR blockade 3E7 – mAB2 No CendR blockade 7E8 - mAB3 Complete CendR blockade |
References: 2 entries
Canturi-Castelvetri et al,. 2020doi:10.1101/2020.06.07.137802
Cantuti-Castelvetri et al. 2020. Science. 370(6518):856-860. PMID: 33082293.
Add a reference
References: 2 entries
Canturi-Castelvetri et al,. 2020doi:10.1101/2020.06.07.137802
Cantuti-Castelvetri et al. 2020. Science. 370(6518):856-860. PMID: 33082293.
Add a reference
